News

InSysBio held its 16th Annual Internal Scientific Meeting. The Meeting combined a warm and welcoming atmosphere with insightful discussions on key priorities and future opportunities, strengthening the team's strong engagement and collaborative spirit.

The project aims at Quantitative Systems Pharmacology modeling of a T-cell engager to identify first-in-human dose and predict optimal step-up dosing regimen

InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the extension of collaboration with BeOne Medicines, a global oncology company.

The project aims at mechanistic PK/RO modeling to predict optimal dose and regimen of BGB-B2033, GPC3 x 4-1BB bispecific antibody

InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with BeOne Medicines, a global oncology company.

InSysBio launches a new data annotation service designed to support researchers and analysts who require specific, literature-based biological data to be added to InSysBio’s CYTOCON or fIVE databases for use in QSP modeling, analysis, or decision-making. The new service allows clients to submit targeted data requests related to diseases, tissues, cell types, and cytokines

InSysBio announces Immune Response Template (IRT) which was previously available under a license model now is completely free to use. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system.

The project aims at translational mechanistic modeling of antibodies to predict human pharmacokinetics and target occupancy in cerebrospinal fluid

InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the extension of collaboration with discoveric bio alpha, a biotechnology company taking next generation antibody technologies into Alzheimer’s Disease.